[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.141.60. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News
October 26, 1964

Federal Bureau of Medicine To Begin Review on Effectiveness of Drugs

JAMA. 1964;190(4):25-26. doi:10.1001/jama.1964.03070170150043

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

The Federal Bureau of Medicine plans to begin a review of several hundred drugs in 13 categories with respect to their efficacy under the Kefauver-Harris Amendments to the Federal Food, Drug, and Cosmetic Act.

Joseph F. Sadusk Jr., MD, medical director of the Food and Drug Administration, said the categories, first announced in May, 1964, will be reviewed according to the following priority:

  1. Proteolytic enzymes (oral and injectable).

  2. Progestational agents.

  3. Drugs offered for apprehensive and anxiety states, most tranquilizers, monoamine oxidase inhibitors.

  4. Nonprescription iron preparations.

  5. Pediatric dosages.

  6. Topical ophthalmic antibiotic combinations.

  7. A number of sustained-release drugs.

  8. Other topical antibiotic combination products.

  9. Bioflavonids.

  10. Hormone creams.

  11. Drugs used in pregnancy.

  12. Topical antihistamines.

  13. Topical 'caines (local anesthetics).

"It must be realized," Sadusk said, "that this order of priority may change with time and indeed certain specific drugs, or even categories

First Page Preview View Large
First page PDF preview
First page PDF preview
×